Home: Oncology Leader Commentary

Click on the topic below for comments by Dr Aman Buzdar to comment on. You will also find links to related articles and clinical trials.

Arimidex as first-line therapy
Toxicity profile of Arimidex
Choice of first-line endocrine therapy for postmenopausal patients
Neoadjuvant anastrozole
ATAC adjuvant trial: Arimidex vs Tamoxifen vs the Combination
Adjuvant tamoxifen in low-risk patients
Adjuvant tamoxifen in premenopausal patients
Adjuvant tamoxifen in patients with DCIS

Home · Contact us
Terms of use and general disclaimer